How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,297 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Recommendations on routine screening pelvic examination

, attitude and practices of women towards pelvic examination and Pap smear in Jamaica. N Am J Med Sci 2010;2(10):478-86. 21. Hesselius I, Lisper HO, Nordstrom A, Anshelm-Olson B, Odlund B. Comparison between participants and non-participants at a gynaecological mass screening. Scand J Soc Med 1975;3(3):129-38. 22. Wijma B, Gullberg M, Kjessler B. Attitudes towards pelvic examination in a random sample of Swedish women. Acta Obstet Gynecol Scand 1998;77(4):422-8. 23. Armstrong L, Zabel E, Beydoun HA (...) examination and ovarian screening: Guidelines International Network, NICE, National Guideline Clearinghouse, US Preventive Services Task Force, and CMA Infobase. Five guidelines were identified; however, only the ACP guideline discussed the role of the pelvic examination, which was the topic of interest • Prescreen ACP guideline: ACP guideline was prescreened according to CTFPHC criteria (guideline must be based on a systematic review of the evidence, and the review must be readily available and must use

2016 CPG Infobase

42. Vertigo control in M‚niŠre's disease following transmyringeal ventilation tube insertion: a systematic review on the current state of the evidence

Vertigo control in M‚niŠre's disease following transmyringeal ventilation tube insertion: a systematic review on the current state of the evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria

2019 PROSPERO

43. Use of M-health as a strategy to improve the cardiovascular performance of cardiac patients belonging to the cardiovascular rehabilitation program

Use of M-health as a strategy to improve the cardiovascular performance of cardiac patients belonging to the cardiovascular rehabilitation program Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria

2019 PROSPERO

44. Effectiveness of M-health applications on hypertension management: a systematic review and meta-analysis of randomized controlled trials

Effectiveness of M-health applications on hypertension management: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion

2019 PROSPERO

45. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update

The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update ISHLT GUIDELINE The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update Mandeep R. Mehra, MD (Chair), Charles E. Canter, MD, Margaret M. Hannan, MD, Marc J. Semigran, MD, Patricia A. Uber, PharmD, David A. Baran, MD, Lara Danziger-Isakov, MD, MPH, James K. Kirklin, MD, Richard Kirk, MD, Sudhir S. Kushwaha (...) , to exclude intrinsic renal disease. It is reasonable to consider the presence of irreversible renal dysfunction (eGFR o 30 ml/min/1.73 m 2 ) as a relative contraindication for heart transplantation alone (Class IIa, Level of Evidence: C). Continued on page 4 Mehra et al. ISHLT Listing Criteria for HT 3Table 1 (Continued) 2006 Guideline recommendation 2016 Guideline recommendation Clinically severe symptomatic cerebrovascular disease, which is not amenable to revascularization, may be considered

2016 International Society for Heart and Lung Transplantation

46. Regular exploratory examination of the need for DMP revision - a feasibility study using the example of the DMP "CHD"

Regular exploratory examination of the need for DMP revision - a feasibility study using the example of the DMP "CHD" Auftrag: Arbeitspapier Version: Stand: GA14-06 1.0 07.10.2014 Regelmäßige orientierende Prüfung des Überarbeitungs- bedarfs der DMP – eine Machbarkeitsstudie am Beispiel des DMP KHK IQWiG-Berichte – Nr. 246 Arbeitspapier GA14-06 Version 1.0 DMP Überprüfung 07.10.2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) - i - Impressum Herausgeber: Institut (...) für Qualität und Wirtschaftlichkeit im Gesundheitswesen Thema: Regelmäßige orientierende Prüfung des Überarbeitungsbedarfs der DMP – eine Machbarkeitsstudie am Beispiel des DMP KHK Interne Auftragsnummer: GA14-06 Anschrift des Herausgebers: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 (KölnTurm) 50670 Köln Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de Internet: www.iqwig.de ISSN: 1864-2500Arbeitspapier GA14-06 Version 1.0 DMP

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

47. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Published in the March 2015 issue of Genetics in M (Full text)

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Published in the March 2015 issue of Genetics in M Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology | Genetics in Medicine Thank you (...) , this recommendation describes a process for classifying variants into these five categories based on criteria using typical types of variant evidence (e.g., population data, computational data, functional data, segregation data). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a Clinical Laboratory Improvement Amendments–approved laboratory

2015 Association for Molecular Pathology

48. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke (Full text)

on Epidemiology and Prevention Bart M. Demaerschalk , Dawn O. Kleindorfer , Opeolu M. Adeoye , Andrew M. Demchuk , Jennifer E. Fugate , James C. Grotta , Alexander A. Khalessi , Elad I. Levy , Yuko Y. Palesch , Shyam Prabhakaran , Gustavo Saposnik , Jeffrey L. Saver , and Eric E. Smith and on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention Originally published 22 Dec 2015 Stroke. 2015;47:581–641 You are viewing the most recent version of this article (...) Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article

2015 American Heart Association

49. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke

for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , MD, MSc, FRCPC, FAHA, Chair , MD, FAHA, Vice-Chair , MD, MS, FAHA , MD , DO , MD , MD, MS, FAHA , MD, MBA, FAHA , PhD , MD, MS, FAHA , MD, MSc, FAHA , and MD, FAHA MD, MPH, FAHAon behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention Bart M. Demaerschalk , Dawn O (...) . Kleindorfer , Opeolu M. Adeoye , Andrew M. Demchuk , Jennifer E. Fugate , James C. Grotta , Alexander A. Khalessi , Elad I. Levy , Yuko Y. Palesch , Shyam Prabhakaran , Gustavo Saposnik , Jeffrey L. Saver , and Eric E. Smith and on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention Originally published 22 Dec 2015 Stroke. 2016;47:581–641 You are viewing the most recent version of this article. Previous versions: Abstract Purpose— To critically review

2015 American Academy of Neurology

50. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography (Full text)

and the rationale for their application to help identify changes in valvar status associated with ARF are discussed below. These changes are listed in and and are analogous to valvular abnormalities also described in RHD in the recent World Heart Federation statement on that condition. Table 3. Doppler Findings in Rheumatic Valvulitis Pathological mitral regurgitation (all 4 criteria met) Seen in at least 2 views Jet length ≥2 cm in at least 1 view Peak velocity >3 m/s Pansystolic jet in at least 1 envelope (...) Pathological aortic regurgitation (all 4 criteria met) Seen in at least 2 views Jet length ≥1 cm in at least 1 view Peak velocity >3 m/s Pan diastolic jet in at least 1 envelope Loading conditions should be accounted for at time of echocardiography/Doppler assessment (see the section Differential Diagnosis of ARF for a full discussion). This table reflects an amalgam of the findings from the references listed in and other guideline statements , and also resembles findings described in rheumatic heart

2015 American Heart Association

51. Medical eligibility criteria for contraceptive use

Medical eligibility criteria for contraceptive use Department of Reproductive Health and Research World Health Organization Avenue Appia 20, CH-1211 Geneva 27 Switzerland Fax: +41 22 791 4171 E-mail: reproductivehealth@who.int www.who.int/reproductivehealth For more information, please contact: COCs Barrier methods IUDs Fertility awareness-based methods Lactational Coitus interruptus Copper IUD for amenorrhoea Patch Female surgical sterilization Intrauterine devices CICs emergency contraception (...) study): incidence ratio 9.2 (95% CI 6.5–13) CI: confidence interval; OR: odds ratio. a Based on 5 studies, 4 of which reported incidence by week and 1 of which reported the proportion of VTE events by week. b Based on 6 studies.Medical eligibility criteria for contraceptive use - Part I | 37 References 1. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol. 2011;117(3):657–62. 2. Petersen JF, Bergholt T, Nielsen AK, Paidas MJ

2015 World Health Organisation Guidelines

52. Harm of HPV vaccine: Latest information and examination of epidemiological studies

Harm of HPV vaccine: Latest information and examination of epidemiological studies MED CHECK - TIP APRIL 2015 / Vol.1 No.1 · Page -The Informed Prescriber C N o 1 M ED HECK Volume 1 April 2 0 1 5 H.pylori eradication may shorten life span CONTENTS (April 2015,Vol. 1, No. 1) Editorial: An independent drug bulletin for medical practice New Products SGLT-2 inhibitors: Unacceptable products -- can we call these “medicines”? Methadone (Limited use): Useful only in opioid rotation with special (...) intervention CD: C. difficile, PPI: Proton pump inhibitor, H 2 -bl: H 2 blocker Review ReviewMED CHECK - TIP APRIL 2015 / Vol.1 No.1 · Page References 1 - a) Check Med TIP team. Metronidazole. Check Med TIP: 2015 Jan: 15(57) : 8-11. b) Check Med TIP team. Neurotoxicity of metronidazole. Check Med TIP: 2015 Mar.: 15(58):40-41. 2 - Prescrire team, Proton pump inhibitors: Clostridium difficile infection. Prescrire International 2013: 22 (142): 239-240. 3 - Matsuki S, Ozaki E, Shozu M et al. Colonization

2015 Med Check - The Informed Prescriber

53. The cost effectiveness of m-health interventions for older adults: a systematic review

text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured (...) The cost effectiveness of m-health interventions for older adults: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

54. Efficacy and safety of intratympanic steroid and gentamicin treatment of M?ni?re's disease: a meta-analysis

analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case (...) Efficacy and safety of intratympanic steroid and gentamicin treatment of M?ni?re's disease: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

55. Betahistine for M?ni?re's disease or syndrome [Cochrane protocol]

: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data (...) Betahistine for M?ni?re's disease or syndrome [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

56. A review of tailored actionable messages sent via mobile technology (m-health) to patients to promote health behaviour and manage medical conditions

A review of tailored actionable messages sent via mobile technology (m-health) to patients to promote health behaviour and manage medical conditions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) " or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening

2018 PROSPERO

57. Comparing the biomechanics of brostr?m, suture anchor, and tape augmentation reconstructions for lateral ankle sprains: a systematic review

. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts (...) Comparing the biomechanics of brostr?m, suture anchor, and tape augmentation reconstructions for lateral ankle sprains: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

58. m-Palliative Care Link: Improving Palliative Care for Late Stage Tanzanian Cancer Patients

m-Palliative Care Link: Improving Palliative Care for Late Stage Tanzanian Cancer Patients m-Palliative Care Link: Improving Palliative Care for Late Stage Tanzanian Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. m-Palliative Care Link: Improving Palliative Care for Late Stage Tanzanian Cancer Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03634696 Recruitment Status : Recruiting First Posted

2018 Clinical Trials

59. Clinical Criteria for the Evaluation of Caries Lesions Around Restorations in Primary Teeth (CARDEC-03)

and then, will be monitored for two years. Reassessments will be performed by a blind examiner in relation to the child's allocation group, and the occurrence of outcomes will be assessed according to predefined criteria described for evaluation of restorations performed in the context of atraumatic restorative treatment. The primary outcome will be the need for restorative intervention during the follow-up of the restorations evaluated by the different criteria. This outcome is composed of several components (...) of the children according to the diagnosis criteria Outcome Measures Go to Primary Outcome Measures : Operative treatment needs of the evaluated restorations (success of restoration) [ Time Frame: 24 months ] The necessity to repair the evaluated restorations during the follow-up examinations will be assessed by the Roeleveld et al. (1996) criteria (scores 11, 12, 13 and 30) or Frencken et al. (1996) criteria (scores 2 and 3). The criteria are described below: Roeleveld et al. (1996): Score 11 - Restoration

2018 Clinical Trials

60. AIUM Practice Parameter for the Performance of an Ultrasound Examination of the Neonatal and Infant Spine

this mission. Practice parameters of the AIUM are intended to provide the medical ultrasound community with parameters for the performance and recording of high-quality ultrasound examinations. The parameters reflect what the AIUM considers the minimum criteria for a complete examination in each area but are not intended to establish a legal stan- dard of care. AIUM-accredited practices are expected to generally fol- low the parameters with recognition that deviations from these param- eters will be needed (...) Pretorius, MD Tatjana Rundek, MD, PhD Khaled Sakhel, MD Ants Toi, MD Isabelle Wilkins, MD neonatalSpine.qxp_0616 6/29/16 4:02 PM Page 7References 1. Guggisberg D, Hadj-Rabia S, Viney C, et al. Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol 2004; 140:1109–1115. 2. Izci Y, Gonul M, Gonul E. The diagnostic value of skin lesions in split cord malformations. J Clin Neurosci 2007; 14:860–863. 3. Kriss VM, Desai NS. Occult spinal dysraphism in neonates: assessment

2016 American Institute of Ultrasound in Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>